Efficacy of Combined Treatment with Clindamycin and Ultrasound in Chronic Pelvic Inflammatory Disease

This investigation sought to examine the clinical effectiveness of utilizing both clindamycin and ultrasound in the management of chronic pelvic inflammatory disease. A retrospective review was undertaken for 102 patients diagnosed with chronic pelvic inflammatory disease who were hospitalized at our facility from August 2020 to August 2023. Clindamycin and conventional nutritional support were provided to the control group, whereas the treatment group received supplementary ultrasound therapy in addition to the control group regimen, and both groups were subjected to uninterrupted treatment for duration of 1 mo. The duration of symptom alleviation, encompassing lumbosacral pain, fatigue, and increased vaginal discharge, was documented during the treatment period. Pre- and post-treatment assessments included the measurement of inflammatory markers (interleukin-1 beta, interleukin-10, and tumor necrosis factor alpha) and immune markers (cluster of differentiation 3(+), cluster of differentiation 4(+) and cluster of differentiation 8(+)). In addition, Doppler ultrasound was employed to analyze the pelvic blood flow dynamics indicators (pulsatility index, resistance index, peak systolic velocity) of the ovarian and uterine arteries. In comparison to the control group, there was a notable enhancement in the blood flow dynamics indicators (pulsatility index, resistance index, peak systolic velocity) of the ovarian and uterine arteries in the treatment group (p<0.05). Moreover, there was no noteworthy variance in the occurrence of adverse reactions between the two groups. The use of clindamycin in conjunction with ultrasound therapy demonstrated favorable clinical effectiveness among individuals with chronic pelvic inflammatory disease by alleviating symptoms, ameliorating the inflammatory condition, adjusting immune function, and enhancing blood circulation.